ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0021201

skin infection

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. skin infection. Diseases, record MONDO_0021201. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021201

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
skin infection
Open Targets
Open Targets ID
MONDO_0021201
Open Targets
NCI Thesaurus
C35025
NCI Thesaurus
Highest stage of its drugs
Approval, for 14 of its 20 drugs, from DailyMed, FDA, PMDA and TTD
Open Targets

Drugs20

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
POVIDONE-IODINECHEMBL1201724ApprovalDailyMed300Drugs and targets
ISOPROPYL ALCOHOLCHEMBL582Small moleculeApprovalDailyMed200Drugs and targets
TETRACYCLINE HYDROCHLORIDECHEMBL454950Small moleculeApprovalDailyMed200Drugs and targets
BACITRACINCHEMBL1200558ProteinApprovalTTD100Drugs and targets
CETRIMIDECHEMBL5219790ApprovalTTD100Drugs and targets
CLOTRIMAZOLECHEMBL104Small moleculeApprovalDailyMed100Drugs and targets
DAPTOMYCINCHEMBL387675Small moleculeApprovalPMDA100Drugs and targets
DELAFLOXACIN MEGLUMINECHEMBL2105638Small moleculeApprovalTTD100Drugs and targets
MENTHOLCHEMBL256087Small moleculeApprovalDailyMed100Drugs and targets
OZENOXACINCHEMBL3990047Small moleculeApprovalPMDA100Drugs and targets

1 to 10 of 20

See all 20 drugs

Targets3

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
AVPR2Vasopressin V2 receptor1Vasopressin V2 receptor antagonistPhase 2https://conductscience.org/library/genes/554Drugs and targets
TRPA1Transient receptor potential cation channel subfamily A member 11Transient receptor potential cation channel subfamily A member 1 openerApprovalhttps://conductscience.org/library/genes/8989Drugs and targets
TRPM8Transient receptor potential cation channel subfamily M member 81Transient receptor potential cation channel subfamily M member 8 openerApprovalhttps://conductscience.org/library/genes/79054Drugs and targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT02530528Pilot Trial of Preoperative Chlorhexidine Gluconate (CHG) Skin PreparationPhase 1/2272021-04-30SurgeryCHLORHEXIDINE GLUCONATEIts record names the diseaseClinicalTrials.gov
NCT01690559Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution704InfectionCIPROFLOXACINOpen Targets' reading of its recordClinicalTrials.gov
NCT01223222A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin InfectionPhase 224Gram-positive, Skin Infections, Mild Eczema/Dermatoses, Atopic DermatitisLTX-109Its record names the diseaseClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021201

GET https://conductscience.org/api/diseases/v1/MONDO_0021201/drugs

API referenceFor AI assistants